Stryker Dirección

Dirección controles de criterios 3/4

El CEO de Stryker's es Kevin Lobo , nombrado en Oct 2012, tiene una permanencia de 11.5 años. compensación anual total es $20.77M, compuesta por 6.7% salario y 93.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.026% de las acciones de la empresa, por valor de €31.49M. La antigüedad media del equipo directivo y de la junta directiva es de 5.6 años y 6.7 años, respectivamente.

Información clave

Kevin Lobo

Chief Executive Officer (CEO)

US$20.8m

Compensación total

Porcentaje del salario del CEO	6.7%
Permanencia del CEO	11.6yrs
Participación del CEO	0.03%
Permanencia media de la dirección	5.7yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kevin Lobo en comparación con los beneficios de Stryker?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	US$21m	US$1m	US$3b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$19m	US$1m	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$16m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$13m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$15m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$4b
Dec 31 2018	US$14m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$14m	US$1m	US$1b

Compensación vs. Mercado: La compensación total de Kevin($USD20.77M) está por encima de la media de empresas de tamaño similar en el mercado Austrian ($USD4.49M).

Compensación vs. Ingresos: La compensación de Kevin ha sido consistente con los resultados de la empresa en el último año.

CEO

Kevin Lobo (58 yo)

11.6yrs

Permanencia

US$20,767,847

Compensación

Mr. Kevin A. Lobo has been the Chief Executive Officer of Stryker Corporation since October 1, 2012 and serves as its President since October 01, 2021. He serves as Chairman of the Board at The Advanced Me...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Lobo	Chairman	11.6yrs	US$20.77m	0.026% $ 30.4m
Glenn Boehnlein	VP & CFO	8.1yrs	US$6.84m	0.0066% $ 7.7m
Viju Menon	Group President of Global Quality & Operations	6.1yrs	US$4.47m	0.0026% $ 3.0m
J. Pierce	Group President of MedSurg & Neurotechnology	5.8yrs	US$6.49m	0.015% $ 17.4m
Spencer Stiles	Group President of Orthopaedics & Spine	5.8yrs	US$6.49m	0.014% $ 15.8m
William Berry	VP & Chief Accounting Officer	2.8yrs	sin datos	0.00069% $ 795.4k
Robert Cohen	CTO and VP of Global R&D - Joint Replacement	no data	sin datos	sin datos
Alan Douville	VP, Chief Information Officer & Chief Information Security Officer	5.7yrs	sin datos	sin datos
Jason Beach	Vice President of Finance & Investor Relations	1.8yrs	sin datos	sin datos
Robert Fletcher	VP & Chief Legal Officer	5.1yrs	US$2.24m	0.0025% $ 2.9m
Dana McMahon	VP & Chief Compliance Officer	no data	sin datos	sin datos
Yin Becker	VP of Communications	5.4yrs	sin datos	0.0082% $ 9.5m

5.7yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SYK es experimentado (5.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Lobo	Chairman	11.6yrs	US$20.77m	0.026% $ 30.4m
Lisa Skeete Tatum	Independent Director	4yrs	US$319.25k	0.00040% $ 461.1k
Howard Cox	Director Emeritus	6yrs	US$38.86k	sin datos
John Brown	Chairman Emeritus	no data	US$286.99k	5.26% $ 6.1b
Ronda Stryker	Independent Director	40.3yrs	US$319.25k	4.94% $ 5.7b
Mary Brainerd	Independent Director	6.8yrs	US$334.25k	0.0013% $ 1.5m
Srikant T. Datar	Independent Director	14.8yrs	US$319.25k	0.0083% $ 9.6m
Allan Golston	Independent Director	13.3yrs	US$334.25k	0.0031% $ 3.6m
Sherilyn S. McCoy	Lead Independent Director	6yrs	US$359.25k	0.00022% $ 253.6k
Rajeev Suri	Independent Director	6yrs	US$319.25k	0.0012% $ 1.4m
Giovanni Caforio	Independent Director	3.4yrs	US$319.25k	0.00040% $ 461.1k
Andrew Silvernail	Independent Director	10.5yrs	US$339.25k	0.0015% $ 1.7m

6.8yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de SYK se considera experimentada (6.7 años de antigüedad promedio).

Stryker Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently sold €93m worth of stock

Insufficient new directors

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Key Executive recently sold €1.3m worth of stock

Independent Director recently sold €130k worth of stock

Recent updates

Stryker Corporation Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$2.07 (vs US$1.56 in 1Q 2023)

Stryker Corporation to Report Q1, 2024 Results on Apr 30, 2024

Stryker Launches Gamma4 Hip Fracture Nailing System in Europe

Upcoming dividend of US$0.80 per share

Fourth quarter dividend of US$0.80 announced

Independent Director recently sold €93m worth of stock

Stryker Announces the Launch of Prophecy Footprint, an Expansion of the Prophecy Surgical Planning System, Offering Comprehensive Surgical Planning Across the Entire Foot

Full year 2023 earnings released: EPS: US$8.34 (vs US$6.24 in FY 2022)

Stryker Corporation Provides Earnings Guidance for the Year 2024

Insufficient new directors

Upcoming dividend of US$0.80 per share at 1.0% yield

Stryker Corporation (NYSE:SYK) executed a binding offer to acquire Serf from SAS Menix.

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Stryker Corporation Declares Quarterly Dividend, Payable on January 31, 2024

Stryker Corporation Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$1.82 (vs US$2.16 in 3Q 2022)

Stryker to Showcase Q Guidance System with Spine Guidance Software

Stryker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Upcoming dividend of US$0.75 per share at 1.0% yield

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Stryker Corporation Releases Its Next-Generation of Advanced Surgical Cameras

Stryker’S Pangea Systems Receive Food & Drug Administration Clearance

Key Executive recently sold €1.3m worth of stock

Stryker Corporation Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$1.94 (vs US$1.73 in 2Q 2022)

Stryker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Upcoming dividend of US$0.75 per share at 1.0% yield

Independent Director recently sold €130k worth of stock

Surgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software

Independent Director recently sold €266k worth of stock

Stryker Corporation Declares Quarter Dividend, Payable on July 31, 2023

First quarter 2023 earnings released: EPS: US$1.56 (vs US$0.85 in 1Q 2022)

Upcoming dividend of US$0.75 per share at 1.1% yield

Stryker’s Q Guidance System for Cranial Applications Receives FDA Clearance

Stryker Declares Quarterly Dividend, Payable on April 28, 2023

VP & CFO recently sold €6.2m worth of stock

Full year 2022 earnings released: EPS: US$6.24 (vs US$5.29 in FY 2021)

Stryker Corporation Provides Earnings Guidance for the Year 2023

Stryker Corporation to Report Q4, 2022 Results on Jan 31, 2023

Upcoming dividend of US$0.75 per share

Stryker Launches Citrefix™ Suture Anchor System

Stryker Corporation Declares Quarterly Dividend, Payable January 31, 2023

Independent Director recently sold €64k worth of stock

Stryker Opens the OR of the Future for Customers to Experience Tomorrow's OR

Insider recently sold €76k worth of stock

Now 17% undervalued

Third quarter 2022 earnings released: EPS: US$2.16 (vs US$1.16 in 3Q 2021)

Stryker Corporation Provides Earnings Guidance for the Year 2022

Stryker Corporation Launches Monterey AI Interbody System with New Pre-Clinical Data

Stryker Launches Q Guidance System with Spine Guidance Software

Upcoming dividend of US$0.69 per share

Stryker Receives FDA Clearance for OptaBlate Bone Tumor Ablation System

Stryker Launches Pulse Intelligent Delivery Platform

Stryker Launches New Gamma4 Hip Fracture Nailing System

Stryker Declares Quarterly Dividend, Payable on October 31, 2022

Stryker Corporation Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released: EPS: US$1.73 (vs US$1.57 in 2Q 2021)

Stryker Corporation to Report Q2, 2022 Results on Jul 26, 2022

Upcoming dividend of US$0.69 per share

Lieff Cabraser & Shavitz Law Group Files Federal Collective and California Class Action Lawsuit Against Stryker Corporation for Failure to Pay Overtime Wages, Provide Meal and Rest Breaks, and Pay Business Expenses

Stryker Receives FDA Clearance for Q Guidance System for Spine Applications

Stryker Corporation Announces Board Changes

Stryker Corporation Declares Quarterly Dividend, Payable July 29, 2022

First quarter 2022 earnings released: EPS: US$0.85 (vs US$0.80 in 1Q 2021)

Stryker Corporation to Report Q1, 2022 Results on Apr 28, 2022

Upcoming dividend of US$0.69 per share

Stryker Launches PROstep™ MICA® SOLO Guide